Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
drug development
-
ACE is the molecular targets of inhibitory drugs that favorably influence diabetic complications
drug development
important drug target because of its role in the regulation of blood pressure via the renin-angiotensin-aldosterone system
drug development
-
marine-derived ACE inhibitors as therapeutic drug candidates to treat hypertension
medicine
-
acein-2 as well as acein-1 can be used as a starting material for anti-hypertensive drugs against ACE
medicine
-
genistein has a potentially preventive role against cardiovascular diseases. Genistein inhibits the expression of angiotensin-converting enzyme via estrogen receptor and subsequently ERK1/2 signaling pathway in rat aortic endothelial cells. Down-regulation of the angiotensin-convering enzyme with a consequent change in circulating levels of angiotensin II, vasorelaxant angiotensin(1-7) and bradykinin plays an important role in cardiovascular effects of genistein through the ERK1/2 pathway
medicine
-
inhibition of the angiotensin-converting enzyme protects against the progression of several cardiovascular diseases. Because of its dual role in regulating angiotensin II and bradikinin levels, the positive clinical effects of ACE inhibitors are thought to be the consequence of concomitant reductions in the production of angiotensin II and the degradation of bradykinin
medicine
-
monoclonal antibodies recognizing the C-terminal domain of human ACE are useful tools for quantification of testicular isoform of angiotensin I-converting enzyme expression on human live and fixed spermatozoa and further adequate analysis of the tACE role in reproduction. The development of adequate quantitative assays of expression of the testicular isoform of angiotensin I-converting enzyme on the surface of ejaculated spermatozoa might be important for further studies about the role of the enzyme in male fertility
medicine
-
the peptide Val-Leu-Ile-Val-Pro is resistant to digestion by proteases of the gastrointestinal tract. The antihypertensive property of this peptide derived from glycinin might find importance in the development of therapeutic functional foods
medicine
-
a combination of angiotensin-converting enzyme inhibitors and diuretic or angiotensin-converting enzyme and calcium channel blockers is effective in lowering blood pressure and decreasing cardiovascular events
medicine
-
ACE2 overexpression may provide a therapeutic strategy for atherosclerosis by inhibiting production of monocyte chemoattractant protein-1 (MCP-1) induced by angiotensin II. ACE2 produces beneficial effects on prevention of atherosclerosis
medicine
-
although angioedema induced by angiotensin-converting enzyme inhibitor is a non-frequent side effect, primary care physicians should be aware of it, informing their patients about these complications and diagnosing it as early as possible
medicine
-
angioedema is a rare but potentially life-threatening adverse effect of angiotensin-converting enzyme inhibitors. Angioedema due to angiotensin-converting enzyme inhibitors usually appears during the first weeks of treatment. Late-onset anioedema is often unrecognized
medicine
-
angioedema provoked by angiotensin-converting enzyme inhibitors. Complement 1 inhibitor is effective in reversing angioedema provoked by angiotensin-converting enzyme inhibitors
medicine
-
angiotensin-converting enzyme inhibition (lisinopril) and AT1 receptor blockade reduce the tubular damage and apoptosis in the contralateral testes after unilateral testicular torsion. The beneficial effect of these drugs may arise from inhibition of ischemic process resulting from increased sympathetic activity and elimination of insults subsequent to dysregulation of the renin-angiotensin system
medicine
-
angiotensin-converting enzyme inhibition confers renoprotection in adriamycin nephropathy by reducing intrarenal angiotensin II and augmenting expression of N-acetylseryl-aspartyl-lysyl-proline that together attenuate signaling of mitogen-activated protein kinase and its downstream proinflammatory and fibrinogenic properties
medicine
-
angiotensin-converting enzyme inhibitors are an important treatment option for hypertension, especially when elevated blood pressure exists in the presence of diabetes mellitus, chronic kidney disease, or congestive heart failure. Inhibition of the renin-angiotensin system when utilized along with other antihypertensive medications is particularly effective in hypertensive patients with type 2 diabetes, chronic kidney disease, and vascular disorders. The effectiveness of blockers of the renin-angiotensin system is enhanced by maximizing the daily dose and combining the medications with thiazide diuretics
medicine
-
angiotensin-converting enzyme inhibitors show beneficial effects on cardiovascular end points. Although angiotensin II receptor blockers have a better side effect profile than angiotensin-converting enzyme inhibitors, angiotensin-converting enzyme inhibitors may remain the treatment of choice in the majority of patients as they are cheaper and have extensive data from randomized trials on their clinical efficiacy
medicine
-
antihypertensive effect of angiotensin I-converting enzyme inhibitory peptides from a sesame protein hydrolysate in spontaneously hypertensive rats. Sesam peptide powder would be a beneficial ingredient for preventing and providing therapy against hypertension and its related diseases
medicine
-
benazepril induces isolated visceral angioedema: a rare and under diagnosed adverse effect of angiotensin converting enzyme inhibitors
medicine
-
casein hydrolysate containing VPP and IPP improves the vascular endothelial dysfunction in subjects with mild hypertension. The continuous intake of VPP and IPP could help to prevent cardiovascular diseases in hypertensive subjects
medicine
-
chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery
medicine
-
chronic inhibition of angiotensin II synthesis from birth specifically reduces the development of adiposity in the rat
medicine
-
combination therapy with an angiotensin-converting enzyme inhibitor and beta-adrenoceptor blocker without intrinsic sympathomimetic activity should be used in the therapy of chronic heart failure
medicine
-
combined use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers improves outcomes in patients with heart failure more than an evidence-based dose of angiotensin-converting enzyme inhibitor alone
medicine
-
despite evidence of fetal complications associated with angiotensin-converting enzyme inhibitor use during pregnancy, the number of pregnant women with pregnancy-related ACE inhibitor exposures increases steadily between 1986-2003. Better methods are needed to reduce fetal exposure to potentially teratogenic prescribed medications
medicine
-
diabetic nephropathy can be delayed by the use of angiotensin-converting enzyme inhibitors
medicine
-
functional variants of the angiotensinogen gene contribute to the variability of antihypertensive responses to angiotensin-converting enzyme inhibitor monotherapy in individuals of African ancestry, with genotype determining wether or not responses occur
medicine
-
in the early phase of diabetes, the angiotensin-converting enzyme inhibitorramipril reverses glomerular overexpression and activation of some critical growth factor pathways and increases protection against oxidative stress. These effects involve B2-kinin receptor activation
medicine
-
increased endothelial NO synthase expression and activity might contribute to the beneficial effects of angiotensin-converting enzyme inhibitor therapy in the treatment of coronary artery disease and heart failure
medicine
-
irbesartan add-on therapy on top of angiotensin-converting enzyme inhibitor and beta-blockers in the treatment of systolic herat failure could further improve symptoms, exercise capacity and quality of life
medicine
-
long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction
medicine
-
modulation of the renin-angiotensin system by enalapril is important for body weight regulation and can be of beneficial effect in the treatment of obesity and related diseases
medicine
-
patients who present to hospital after an overdose of angiotensin converting enzyme inhibitor should be considered for discharge if hypotension has not occurred within 6 h of ingestion
medicine
-
patients with hypertension due to primary aldosteronism are sometimes placed on angiotensin-converting enzyme inhibitors in accordance with guidelines applying to the general hypertensive population. The authors believe this practice is inappropriate because of the inability of angiotensin-converting enzyme inhibitors to lower blood pressure in patients with low renin levels. Pleiotropic effects of angiotensin-converting enzyme inhibitors are unlikely to provide significant benefits in the absence of blood pressure reduction. Angiotensin-converting enzyme inhibitors should be discouraged for the majority of patients with primary aldosteronism, even in face of renal or cardiac disease
medicine
-
patients with left ventricular dysfunction have an increased risk of adverse events leading to discontinuation on angiotensin-converting enzyme inhibitor/angiotensin receptor blocker combination therapy compared with angiotensin-converting enzyme inhibitor alone. This excess risk, coupled with a lack of consistent mortality benefit, suggests that angiotensin receptor blocker should not routinely be added to angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction
medicine
-
peptide derived from tuna dark muscle would be a beneficial ingredient for functional food or pharmaceuticals against hypertension and its related diseases
medicine
-
pooled meta-analysis of randomized placebo-controlled trials suggests that tissue angiotensin-converting enzyme inhibitors modestly reduce the risk of myocardial infarction and cardiovascular death and tend to reduce overall mortality in diabetic patients without left ventricular systolic dysfunction or heart failure
medicine
-
possible cardioprotective effect of during treatment of American tegumentary leishmaniasis with meglumine antimoniate
medicine
-
purified human ACE converts amyloid beta-protein1-42 to amyloid beta-protein1-40. ACE regulates Abeta1-42/Abeta1-40 ratio in vivo by converting secreted Abeta1-42 to Abeta1-40 and degrading Abetas. The upregulation of ACE activity can be a novel therapeutic strategy for Alzheimers disease
medicine
-
purified human ACE converts amyloid beta-protein1-42 to amyloid beta-protein1-40. ACE regulates Abeta142/Abeta1-40 ratio in vivo by converting secreted Abeta1-42 to Abeta140 and degrading Abetas. The upregulation of ACE activity can be a novel therapeutic strategy for Alzheimers disease
medicine
-
renin-angiotensin system-inhibiting drugs seem to protect against cancer in individuals with the DD genotype, which is associated with high levels of angiotensin I-converting enzyme
medicine
-
short-term ramipril treatment adequately reduces angiotensin-converting enzyme activity and blood pressure, but has no significant effects on insulin sensitivity, forearm blood flow, substrate fluxes across the forearm, whole-body substrate oxidation and intramuscular triacylglycerol content in obese insulinresistant subjects
medicine
-
standing and supine blood pressure decreases significantly in both autosomal-dominant polycystic kidney disease patients and controls after the administration of enalapril on low and high-sodium intakes, with no differences between the two groups
medicine
-
the expression level of G-protein coupled receptor kinase mRNA shows the severity of CHF. Angiotensin converting enzyme inhibitor abolishes the enhanced expression of G-protein coupled receptor kinase. Angiotensin converting enzyme inhibitor mediated transcriptional regulation of G-protein coupled receptor kinase gene documents a mechanism of beta-adrenergic receptor regulation, and may provide, at least in part, a potential mechanism responsible for the beneficial effect of angiotensin converting enzyme inhibitor in the treatment of congestive heart failure
medicine
-
the use of angiotensin-converting enzyme inhibitors is associated with a significant reduction in pneumonia risk and, apart from blood pressure-lowering properties, may be useful in the prevention of pneumonia in patients with diabetes
medicine
-
the use of spironolactone and angiotensin-converting enzyme inhibitor combination, in general practice, is largely inappropriate. This could explain an increased incidence of severe hyperkalemia. A risk management plan is needed to obtain a careful selection of patients who derive benefit from therapy and to minimise the risk of hyperkalemia
medicine
-
treating heart failure patients with angiotensin-converting enzyme inhibitors may result in zinc deficiency
medicine
-
treatment with angiotensin-converting enzyme inhibitors is of benefit in reducing the progression of renal damage in young patients with moderately proteinuric IgA nephropathy
medicine
-
triple blockade (addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker) of the renin-angiotensin-aldosterone system is effective for the treatment of proteinuria in patients with non-diabetic nephropathy whose increased urinary protein had not responded sufficiently to a dual blockade
medicine
-
ACE inhibition is a therapeutic target in treating peripheral occlusive arterial disease
medicine
-
ACE inhibitors may contribute to the reduction of the risk of community-acquired pneumonia
medicine
-
ACE is associated with stable coronary artery disease
medicine
-
angiotensin-converting enzyme is a potential target for treatment of Alzheimer's disease
medicine
-
ACE is an ideal target, clinically and nutritionally, in the treatment of hypertension
medicine
-
angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers decrease cardiovascular mortality and slow the progression of renal disease in non-transplant patients. Their impact on kidney transplant is associated with a better graft survival, overview
medicine
-
enzyme inhibition, leading to bradykinin potentiation, is a therapeutic strategy in heart failure for bradykinin-induced systemic arterial vasodilatation
medicine
-
enzyme inhibitors are useful in treatment of hypertension and heart failure, as well as for peritoneal dialysis patients, because inhibit the local tissue renin-angiotensin system, which results in less development of peritoneal fibrosis and a longer life for the peritoneal membrane, overview
medicine
-
evaluation of effects of angiotensin-converting enzyme inhibitors and pharmacogenetic interaction on the survival of the patients with diastolic heart failure, overview
medicine
hypertension is a global health problem, and angiotensin I (ANG I)-converting enzyme (ACE) inhibitors are largely used to control this pathology
medicine
-
chronic inhibition of angiotensin II synthesis from birth specifically reduces the development of adiposity in the rat
-
medicine
-
hypertension is a global health problem, and angiotensin I (ANG I)-converting enzyme (ACE) inhibitors are largely used to control this pathology
-
veterinary medicine
-
angiotensin-converting enzyme inhibitors are recommended in dogs and cats with chronic renal failure. They decrease the glomerular capillary pressure, have antiproteinuric effects, tend to delay the progression of chronic renal failure and to limit the extent of renal lesions
veterinary medicine
-
angiotensin-converting enzyme inhibitors are recommended in dogs and cats with chronic renal failure. They decrease the glomerular capillary pressure, have antiproteinuric effects, tend to delay the progression of chronic renal failure and to limit the extent of renal lesions
veterinary medicine
-
candesartan (angiotensin II type 1 receptor blocker) and enalapril (angiotensin-converting-enzyme inhibitor) during healing after reperfused ST-elevation myocardial infarction prevent rather than worsen adverse remodeling of infarct zone collagens and left ventricular diastolic dysfunction, supporting the clinical use of ARBs and ACEIs during subacute reperfused ST-elevation myocardial infarction
veterinary medicine
-
the combination of an angiotensin converting enzyme inhibitor and spironolactone is safe in elderly small dogs with mitral valve disease with normal serum urea nitrogen and creatinine concentrations